The BRCA patent controversies: An international review of patent disputes

Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA

Volumn , Issue , 2014, Pages 151-174

  van Zimmeren, Esther ^a,b   Nicol, Dianne ^c,d   Gold, Richard ^e   Carbone, Julia ^g   Chandrasekharan, Subhashini ^f   Baldwin, A Lane ^g   Cook Deegan, Robert ^f  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF TASMANIA   (Australia)

^d Centre for Law and Genetics   (Australia)

^e MCGILL UNIVERSITY   (Canada)

^f DUKE UNIVERSITY   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906647516     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203385517     Document Type: Chapter

References (66)

1. Abbott, A. (2005) 'Genetic patent singles out Jewish women', Nature, 436: 12.
2. ACIP (2005) Patents and Experimental Use. www.acip.gov.au/reviews_completed.html
3. Akamai Technologies v. Limelight Networks, Inc. and McKesson Technologies, Inc. v. Epic Systems Corp, (Fed. Cir. 2012) (en banc).
4. ALRC (2004) Genes and Ingenuity: Gene Patenting and Human Health, Report No. 99. www.alrc.gov.au/publications/report-99
5. AMP v. Myriad, 569 U.S. (2013).
6. AMP v. USPTO, 653 F.3d 1329 (Fed. Cir. 2011).
7. AMP v. USPTO, 702 F. Supp. 2d 181 (S.D.N.Y. 2010).
8. Australian Government (2011) Response to Senate Community Affairs References Committee Gene Patents Report. www.ipaustralia.gov.au/about-us/what-we-do/gene-patents-response
9. Australian Senate Community Affairs Committee (2010) Report on Gene Patents. www.aph.gov.au/senate/committee/clac_ctte/gene_patents_43/report/index.htm
10. Australian Senate Legal and Constitutional Affairs Legislation Committee (2011) Report on the Patent Amendment (Human Genes and Biological Materials) Bill 2010. www.aph.gov.au/senate/committee/legcon_ctte/patent_amendment/report/index.htm
11. Baldwin, A. L. and Cook-Deegan, R. (2013) 'Constructing narratives of heroism and villainy: a case study of Myriad's BRACAnalysis and Genentech's Herceptin', Genome Medicine, 5.
12. Benowitz, S. (2003) 'European groups oppose Myriad's latest patent on BRCA1', Journal of the National Cancer Institute, 95: 8-9.
13. Brody, B. (2007) 'Intellectual property and biotechnology: the European debate', Kennedy Institute of Ethics Journal, 17: 69-110.
14. Canadian Biotechnology Advisory Committee (2006) Human Genetic Materials, Intellectual Property and the Health Sector. Ottawa: CBAC.
15. Cancer Voices Australia v. Myriad Genetics, Inc. [2013] FCA 63.
16. Check, E. (2002) 'Malta provides loophole for breast-cancer screen', Nature, 419: 767.
17. Cho, M.K., Illangasekare, S., Weaver, M.A., Leonard, D.G.B., Merz, J.F. (2003) 'Effects of patents and licenses on the provision of clinical genetic testing services', Journal of Molecular Diagnostics, 5: 3-8.
18. Council and European Parliament (1998) Directive 98/44 of the European Parliament and of the Council of 6 July 1998 on the Legal Protection of Biotechnological Inventions, OJ L2013/13.
19. Danish Council of Bioethics (2004) Patenting Human Genes and Stem Cells. Copenhagen: Danish Council of Bioethics.
20. Davies, J. and White, M. (1996) Breakthrough: The Race to Find the Breast Cancer Gene. USA: Wiley and Sons.
21. Debrulle, J., De Cort, L. and Petit M. (2007) 'La licence obligatoire belge pour raisons de santé publique'. In Van Overwalle, G. (ed.) Gene Patents and Public Health. Brussels: Bruylant.
22. EPC (1973) Convention on the Grant of European Patents (European Patent Convention) of 5 October, 1973, as revised by the Act revising Article 63 EPC of 17 December, 1991, and the Act revising the EPC of 29 November, 2000, Decision Administrative Council of the European Patent Organisation of 28 June, 2001, OJ EPO 2001, Special edition 4: 55.
23. ESHG Working Party on Patenting and Licensing (2008) 'Patenting and licensing in genetic testing - recommendations of the European Society of Human Genetics', European Journal of Human Genetics, 16: S3-S9.
24. Gold, E. G. and Carbone, J. (2010) 'Myriad Genetics: in the eye of the policy storm', Genetics in Medicine, 12, 4 Suppl.: S39-S70.
25. Gold, E. G. and Gallochat, A. (2001) 'The European biotech directive: past as prologue', European Law Journal, 7: 331-66.
26. Hall, J. M., Lee, M. K., Newman, B. et al. (1990) 'Linkage of early-onset familial breast cancer to chromosome 17q21', Science, 250: 1684-1689.
27. Holman, C. M. (2012) 'Debunking the myth that whole-genome sequencing infringes thousands of gene patents', Nature Biotechnology, 30: 240-44.
28. Lecrubier, A. (2002) 'European institutions are challenging Myriad Genetics patent monopoly on the BRCA gene', EMBO Reports, 3: 1120-22.
29. Llewelyn M. (2003) Implications of Intellectual Property Rights on Public Healthcare: The UK as Case Study, ATRIP Annual Congress, Tokyo, 4-6 August.
30. Marshall, E. (1997)'The battle over BRCA1 goes to court, BRCA2 may be next', Science, 278: 1874.
31. Matthijs, G. and Halley, D. (2002) 'European-wide opposition against the breast cancer gene patents', European Journal of Human Genetics, 10: 783-84.
32. Mayo v. Prometheus, 132 S.Ct. 1289 (2012).
33. Merrill, S.A. and Mazza, A-M. (eds.) (2006) Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health, Washington, D.C., National Academies Press
34. Miki, Y., Swensen, J., Shattuck-Eidens, D. et al. (1994) 'A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1', Science, 266: 66-71.
35. Murphy, P.D., Allen A.C., Alvares C.P. et al. (1997) Consensus Sequence of the Human BRCA1 Gene, United States patent application, 5 August.
36. Murray, K. and van Zimmeren, E. (2011) 'Dynamic patent governance in Europe and the United States: the Myriad example', Cardozo Journal of International and Comparative Law, 19: 287-342.
37. Myriad Genetics, Inc. (2013) 2012 Annual Report, Salt Lake City.
38. National Research and Development Corporation v. Commissioner of Patents (1959) 102 CLR 252.
39. Nicol, D. (2005) 'Balancing innovation and access to healthcare through the patent system - an Australian perspective', Community Genetics, 8: 228-34.
40. Nicol, D. (2010) 'Collaborative licensing in biotechnology: a survey of knowledge, experience and attitudes in Australia', Biotechnology Law Report, 29: 465-83.
41. Nicol, D. and Nielsen, J. (2003) Patents and Medical Biotechnology: An Empirical Analysis of Issues Facing the Australian Industry. Hobart: Centre for Law and Genetics Occasional Paper No. 6.
42. NIH (2004) 'Best practices for the licensing of genomic inventions', Federal Register 69.
43. Nuffield Council of Bioethics (2002) The Ethics of Patenting DNA. London: Nuffield Council of Bioethics.
44. OECD (2002) Genetic Inventions, IPR and Licensing Practices. Paris: OECD.
45. OECD (2006) Guidelines for the Licensing of Genetic Inventions. Paris: OECD.
46. Ontario Ministry of Health and Long-Term Care (2002) Genetics, Testing and Gene Patenting: Charting New Territory in Healthcare. Ontario: Ontario Ministry of Health and Long-Term Care.
47. Parathasarathy, S. (2007) Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Health Care. Cambridge: MIT Press.
48. Piper, T. and Gold, E. R. (2008) Practices, Policies and Possibilities in Licensing in Human Genetics. Report for Health Canada, Montreal, Canada: The Innovation Partnership. www.theinnovationpartnership.org/data/documents/00000015-1.pdf
49. Price, W. N. (2012) 'Unblocked future: why gene patents won't hinder whole genome sequencing and personalized medicine', Cardozo Law Review, 33: 1601-32.
50. Puget, N., Stoppa-Lyonnet, D., Sinilnikova, O. et al. (1999) 'Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions', Cancer Research, 59: 455-61.
51. Richer, J., Nelson, T. N., Evans, J. Armstrong, L. Lauzon, J. and McGillivray, B. (2012) 'CCMG statement on gene patents', Clinical Genetics, 82: 405.
52. SACGHS (2010) Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests. http://oba.od.nih.gov/oba/sacghs/reports/SACGHS_patents_report_2010.pdf
53. Shattuck-Eidens, D. M., Simard, J., Durocher, F., Emi, M. and Nakamura, Y. (1997) Linked Breast And Ovarian Cancer Susceptibility Gene, United States patent application, 2 December.
54. Standing Committee on Health, Parliament of Canada (2001) Assisted Human Reproduction: Building Families. Ottawa, Canada: Standing Committee on Health Parliament of Canada.
55. Stanford University (2007) 'In the public interest: nine points to consider in licensing university technology'. http://otl.stanford.edu/documents/whitepaper-10.pdf
56. TRIPs (1994) Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPsAgreement). Annex 1C to the Marrakesh Agreement establishing the World Trade Organization (Marrakesh, Morocco, 15 April, 1994).
57. UC v. Lilly, 119 F.3d 1559 (1997).
58. Van Overwalle, G. (ed.) (2007) Gene Patents and Public Health. Brussels: Bruylant.
59. Van Overwalle, G. and van Zimmeren, E. (2006) 'Reshaping Belgian patent law: the revision of the research exemption and the introduction of a compulsory license for public health', IIP Forum, 64: 42-49.
60. van Zimmeren, E. (forthcoming) 'European patent reform: transforming the governance network and enhancing innovation?'. In E. Sorensen, A. K. Hagedorn, B. Damgaard and A. Agger (eds) Public Innovation in Europe. Bentham Science.
61. van Zimmeren, E. and Requena, G. (2007) 'Ex-officio licensing in the medical sector: the French model'. In: Van Overwalle, G. (ed.) Gene Patents and Public Health. Brussels: Bruylant, 123-47.
62. van Zimmeren, E., Vanneste, S., Matthijs, G., Vanhaverbeke, W., Van Overwalle, G. (2011) 'Patent pools and clearinghouses in the Life Sciences', Trends in Biotechnology, 29: 569-76.
63. van Zimmeren, E. and Van Overwalle, G. (2011) 'A paper tiger? Compulsory license regimes for public health in Europe', IIC, 42: 4-40.
64. White, N. L. (2007) 'Time waits for no man: deciding when to file a patent application in Europe', Nature Biotechnology, 25: 639-41.
65. WHO (2005) Genetics, Genomics and the Patenting of DNA: Review of Potential Implications for Health in Developing Countries. Geneva. www.who.int/genomics/FullReport.pdf
66. Williams-Jones, B. (2002) 'History of a gene patent: tracing the development and application of commercial BRCA testing', Health Law Journal, 10: 123-46.